Hepatic injury associated with bevacizumab use in metastatic breast and colon cancers: A review of two cases

Community Oncology

Volumn 5, Issue 10, 2008, Pages 539-542

  Brown Glaberman, Ursa ^a   Swart, Rachael ^a   Dragovich, Tomislav ^a   Bracamonte, Erika ^a   Kurtin, Sandra ^a   Stopeck, Alison ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BRCA2 PROTEIN; CAPECITABINE; CYCLOPHOSPHAMIDE; DOXAZOSIN; DOXORUBICIN; ENOXAPARIN; FLUOROURACIL; FOLINIC ACID; OMEPRAZOLE; OXALIPLATIN; PACLITAXEL; RANITIDINE; TAMOXIFEN;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BREAST CANCER; CANCER RADIOTHERAPY; CASE REPORT; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; FATTY LIVER; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER HISTOLOGY; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; PARTIAL MASTECTOMY; PORTAL HYPERTENSION; RECURRENT CANCER; REOPERATION; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

EID: 56049086883     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70508-3     Document Type: Article

References (25)

1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
2. Giantonio BJ, Catalano P, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-1544.
3. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006;33(5 suppl 10)S26-S34.
4. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-799.
5. Miller KD, Wang M, Garlow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676.
6. Grothey A. Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer. Oncology (Williston Park) 2006;24(14 suppl 10):21-28.
7. Hui CK, Yuen MF, Ng IO, Tsang KW, Fong GC, Lai CL. Low molecular weight heparin-induced liver toxicity. J Clin Pharmacol 2001;41:691-694.
8. Lebrec D, Benhamou JP. Noncirrhotic intrahepatic portal hypertension. Semin Liver Dis 1986;6:332-340.
9. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15:460-466.
10. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastasis. J Clin Oncol 2006;13:2065-2071.
11. Tobon GJ, Canas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol 2007;26:578-581.
12. Menghini VV, Arora AS. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 2001;76:84-86.
13. Germano V, Picchianti Diamanti A, Baccano G, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005;64:1519-1520.
14. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002;99:2310-2314.
15. Reynaert H, Chavez M, Geerts A. Vascular endothelial growth factor and liver regeneration. J Hepatol 2001;34:759-761.
16. Skillings JR, Johnson DH, Miller K, et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. J Clin Oncol 2005;23(16S):3019.
17. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003;21:3542.
18. Lee AY. Epidemiology and management of venous thromboembolism in patients with cancer. Thromb Res 2003;110:167-172.
19. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 2004;50:187-196.
20. Donadon M, Vauthey JN, Loyer EM, Charnsangavej C, Abdalla EK. Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases. World J Gastroenterol 2006;12:6556-6558.
21. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005;200:845-853.
22. Lee Villano J, Mehta D, Radhakrishnan L. Abraxane induced life-threatening toxicities with metastatic breast cancer and hepatic insufficiency. Invest New Drugs 2006;24:455-456.
23. Abraxis [package insert]. Schaumburg, IL: Abraxis: A Division of American Pharmaceutical Partners; 2005.
24. Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005;27:23-44.
25. Nikolic-Tomasevic Z, Jelic S, Cassidy J, Filipovic-Ljeskovic I, Tomasevic Z. Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis. Cancer Chemother Pharmacol 2005;56:594-602.